Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic
07:09pm, Wednesday, 05'th Jun 2024
At least 11 generic versions of Novo Nordisk's popular diabetes drug Ozempic are in the final stages of clinical trials in China, as developers seek to profit from an early patent expiry of the therap
Focus: Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
07:06pm, Wednesday, 05'th Jun 2024
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight los
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
05:37pm, Wednesday, 05'th Jun 2024
The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that pro
Novo Resources Corp. Announces Resignation of Ross Hamilton as Director
04:00pm, Tuesday, 04'th Jun 2024
VANCOUVER, British Columbia, June 04, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) advises that Mr Ross Hamilton has resigned as a directo
Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock
09:53am, Tuesday, 04'th Jun 2024
A couple of new scientific studies on Ozempic were just published. Both indicate that the medicine could be useful in treating addiction.
Beyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight
02:14pm, Monday, 03'rd Jun 2024
As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.
Novo Nordisk A/S - share repurchase programme
10:05am, Monday, 03'rd Jun 2024
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®
10:00am, Monday, 03'rd Jun 2024
Designed to celebrate diverse, unique portrayals of individuals who partner with their healthcare professional to change the course of their weight-management journey, while educating on the clinical
Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks
08:10am, Monday, 03'rd Jun 2024
Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
09:30am, Sunday, 02'nd Jun 2024
Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results.
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
08:25am, Sunday, 02'nd Jun 2024
The vast majority of patients using GLP-1 agonists such as Ozempic and Wegovy are being treated for diabetes or chronic weight management. GLP-1 medications are believed to have further applications,
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
10:25am, Saturday, 01'st Jun 2024
Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
08:00am, Saturday, 01'st Jun 2024
Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.
Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?
01:20pm, Friday, 31'st May 2024
Novo Nordisk stock traded close to a buy point Friday afternoon as shares bounced from their 21-day line this week.
Fat profits from obesity? Goldman Sachs forecasts weight loss market will hit $130bn by 2030
10:58am, Friday, 31'st May 2024
Goldman Sachs predicts that the global market for obesity treatments will surge to $130 billion by 2030, up from an earlier estimate of $100 billion. This revised forecast reflects the growing demand
